BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

525 related articles for article (PubMed ID: 24755884)

  • 1. Oncogenic KRAS signalling in pancreatic cancer.
    Eser S; Schnieke A; Schneider G; Saur D
    Br J Cancer; 2014 Aug; 111(5):817-22. PubMed ID: 24755884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS: feeding pancreatic cancer proliferation.
    Bryant KL; Mancias JD; Kimmelman AC; Der CJ
    Trends Biochem Sci; 2014 Feb; 39(2):91-100. PubMed ID: 24388967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
    Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
    Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
    Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
    Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer.
    Yao W; Rose JL; Wang W; Seth S; Jiang H; Taguchi A; Liu J; Yan L; Kapoor A; Hou P; Chen Z; Wang Q; Nezi L; Xu Z; Yao J; Hu B; Pettazzoni PF; Ho IL; Feng N; Ramamoorthy V; Jiang S; Deng P; Ma GJ; Den P; Tan Z; Zhang SX; Wang H; Wang YA; Deem AK; Fleming JB; Carugo A; Heffernan TP; Maitra A; Viale A; Ying H; Hanash S; DePinho RA; Draetta GF
    Nature; 2019 Apr; 568(7752):410-414. PubMed ID: 30918400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic KRAS Induces NIX-Mediated Mitophagy to Promote Pancreatic Cancer.
    Humpton TJ; Alagesan B; DeNicola GM; Lu D; Yordanov GN; Leonhardt CS; Yao MA; Alagesan P; Zaatari MN; Park Y; Skepper JN; Macleod KF; Perez-Mancera PA; Murphy MP; Evan GI; Vousden KH; Tuveson DA
    Cancer Discov; 2019 Sep; 9(9):1268-1287. PubMed ID: 31263025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical role of oncogenic KRAS in pancreatic cancer (Review).
    Liu J; Ji S; Liang C; Qin Y; Jin K; Liang D; Xu W; Shi S; Zhang B; Liu L; Liu C; Xu J; Ni Q; Yu X
    Mol Med Rep; 2016 Jun; 13(6):4943-9. PubMed ID: 27121414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EVI1 oncogene promotes KRAS pathway through suppression of microRNA-96 in pancreatic carcinogenesis.
    Tanaka M; Suzuki HI; Shibahara J; Kunita A; Isagawa T; Yoshimi A; Kurokawa M; Miyazono K; Aburatani H; Ishikawa S; Fukayama M
    Oncogene; 2014 May; 33(19):2454-63. PubMed ID: 23752186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disruption of p16 and activation of Kras in pancreas increase ductal adenocarcinoma formation and metastasis in vivo.
    Qiu W; Sahin F; Iacobuzio-Donahue CA; Garcia-Carracedo D; Wang WM; Kuo CY; Chen D; Arking DE; Lowy AM; Hruban RH; Remotti HE; Su GH
    Oncotarget; 2011 Nov; 2(11):862-73. PubMed ID: 22113502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance of acinar cell organization is critical to preventing Kras-induced acinar-ductal metaplasia.
    Shi G; DiRenzo D; Qu C; Barney D; Miley D; Konieczny SF
    Oncogene; 2013 Apr; 32(15):1950-8. PubMed ID: 22665051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging role of the KRAS-PDK1 axis in pancreatic cancer.
    Ferro R; Falasca M
    World J Gastroenterol; 2014 Aug; 20(31):10752-7. PubMed ID: 25152578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ciliogenesis and Hedgehog signalling are suppressed downstream of KRAS during acinar-ductal metaplasia in mouse.
    Bangs FK; Miller P; O'Neill E
    Dis Model Mech; 2020 Jul; 13(7):. PubMed ID: 32571902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutant KRAS is a druggable target for pancreatic cancer.
    Zorde Khvalevsky E; Gabai R; Rachmut IH; Horwitz E; Brunschwig Z; Orbach A; Shemi A; Golan T; Domb AJ; Yavin E; Giladi H; Rivkin L; Simerzin A; Eliakim R; Khalaileh A; Hubert A; Lahav M; Kopelman Y; Goldin E; Dancour A; Hants Y; Arbel-Alon S; Abramovitch R; Shemi A; Galun E
    Proc Natl Acad Sci U S A; 2013 Dec; 110(51):20723-8. PubMed ID: 24297898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central role of Yes-associated protein and WW-domain-containing transcriptional co-activator with PDZ-binding motif in pancreatic cancer development.
    Rozengurt E; Eibl G
    World J Gastroenterol; 2019 Apr; 25(15):1797-1816. PubMed ID: 31057295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma.
    Ling J; Kang Y; Zhao R; Xia Q; Lee DF; Chang Z; Li J; Peng B; Fleming JB; Wang H; Liu J; Lemischka IR; Hung MC; Chiao PJ
    Cancer Cell; 2012 Jan; 21(1):105-20. PubMed ID: 22264792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequencies and prognostic role of KRAS and BRAF mutations in patients with localized pancreatic and ampullary adenocarcinomas.
    Schultz NA; Roslind A; Christensen IJ; Horn T; Høgdall E; Pedersen LN; Kruhøffer M; Burcharth F; Wøjdemann M; Johansen JS
    Pancreas; 2012 Jul; 41(5):759-66. PubMed ID: 22699145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS.
    Zhao WG; Yu SN; Lu ZH; Ma YH; Gu YM; Chen J
    Carcinogenesis; 2010 Oct; 31(10):1726-33. PubMed ID: 20675343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KRAS mutant allele-specific imbalance is associated with worse prognosis in pancreatic cancer and progression to undifferentiated carcinoma of the pancreas.
    Krasinskas AM; Moser AJ; Saka B; Adsay NV; Chiosea SI
    Mod Pathol; 2013 Oct; 26(10):1346-54. PubMed ID: 23599154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-206 functions as a pleiotropic modulator of cell proliferation, invasion and lymphangiogenesis in pancreatic adenocarcinoma by targeting ANXA2 and KRAS genes.
    Keklikoglou I; Hosaka K; Bender C; Bott A; Koerner C; Mitra D; Will R; Woerner A; Muenstermann E; Wilhelm H; Cao Y; Wiemann S
    Oncogene; 2015 Sep; 34(37):4867-78. PubMed ID: 25500542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic signaling pathways in pancreatic ductal adenocarcinoma.
    Agrawal R; Natarajan KN
    Adv Cancer Res; 2023; 159():251-283. PubMed ID: 37268398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.